R. Michael Carruthers - 20 Sep 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Signature
/s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers
Issuer symbol
EWTX
Transactions as of
20 Sep 2024
Net transactions value
-$3,388,569
Form type
4
Filing time
24 Sep 2024, 20:22:56 UTC
Previous filing
14 Aug 2024
Next filing
08 Oct 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $88,911 +46,068 +128% $1.93 81,996 20 Sep 2024 Direct F1
transaction EWTX Common Stock Sale $1,316,909 -46,068 -56% $28.59 35,928 20 Sep 2024 Direct F2
transaction EWTX Common Stock Sale $116,174 -4,064 -11% $28.59 31,864 20 Sep 2024 Direct F2
transaction EWTX Common Stock Sale $713,512 -24,960 -78% $28.59 6,904 20 Sep 2024 Direct F3
transaction EWTX Common Stock Options Exercise $96,500 +50,000 +724% $1.93 56,904 20 Sep 2024 Direct
transaction EWTX Common Stock Sale $1,427,385 -50,000 -88% $28.55 6,904 20 Sep 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -96,068 -70% $0.000000 40,990 20 Sep 2024 Common Stock 96,068 $1.93 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,596 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the "ESPP"). 2,898 shares purchased on November 15, 2023 pursuant to the ESPP were properly reported on a Form 4 filed June 26, 2023 but erroneously added again to the balance reported on a Form 4 filed May 3, 2024.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.79, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.81 to $29.06, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.95, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.